<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> is the most common <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> associated with increased mortality and morbidity </plain></SENT>
<SENT sid="1" pm="."><plain>Its management requires high healthcare expenditures; 52%-70% of expenses for AF care are constituted by hospitalization costs </plain></SENT>
<SENT sid="2" pm="."><plain>The current management strategies of pharmacological rhythm control and pharmacological or invasive rate control show no difference in impact on major outcomes in patients with AF </plain></SENT>
<SENT sid="3" pm="."><plain>Radiofrequency catheter ablation (RFA) has been shown to reduce the risk of AF recurrence, improve quality of life and reduce hospitalization rate as compared to pharmacological rhythm control and rate control strategies </plain></SENT>
<SENT sid="4" pm="."><plain>This review summarizes current knowledge on cost and cost-effectiveness analysis of RFA for patients with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
</text></document>